Frequent Links
EmbryologyAngiogenesisstructure determination peer review journalsHeridity Scholarly Peer-review JournalResearch articles in proteomicsEarth scienceBioinformatics cardiac pharmacology innovationsSexual behavior in adultsgenomics group journals listAutoimmune Diseases Cellular stress Top Open Access JournalsAutomation-new-findingsKidney TransplantationArticles On Pharmacogenomics
Otenabant
| File:Otenabant.svg | |
| Systematic (IUPAC) name | |
|---|---|
| 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)piperidine-4- carboxamide | |
| Clinical data | |
| Identifiers | |
| 686344-29-6 7px | |
| None | |
| PubChem | CID 10052040 |
| ChemSpider | 8227602 7px |
| UNII | J8211Y53EF 7px |
| KEGG | D09362 7px |
| ChEMBL | CHEMBL562668 7px |
| Chemical data | |
| Formula | C25H25Cl2N7O |
| 510.4 g/mol | |
| |
| 14px (what is this?) (verify) | |
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
- ^ Kim, M. et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
- ^ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
- ^ http://www.pfizer.com
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
Lua error in package.lua at line 80: module 'Module:Buffer' not found.